Drug Index



Mechanism :

Basiliximab is a chimeric (murine/human) monoclonal antibody (IgG1k), produced by recombinant DNA technology, that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2Ra, also known as CD25 antigen) on the surface of activated T-lymphocytes.

Indication :

• Prophylaxis of acute organ rejection in patients receiving renal transplantation.

Contraindications :

Contraindicated in patients with known hypersensitivity to basiliximab or any other component of the formulation.

Dosing :

>35 kg: 20 mg IV within 2 hours before transplant, followed by 20 mg IV for 4 days following transplant (same as in adults);

<35 kg: 10 mg IV within 2 hours before transplant, followed by 10 mg IV for 4 days following transplant.

The second dose should be withheld if complications such as severe hypersensitivity reactions or graft loss occur.

Adverse Effect :

Constipation, nausea, abdominal pain, vomiting, diarrhea, dyspepsia, anaphylaxis, pain, peripheral edema, fever, hyperkalemia, hypokalemia, hyperglycemia, hypercholesterolemia, hypophosphatemia, hyperuricemia, dyspnea, acne, hypertension, headache, tremor, insomnia, anemia, infections.

Interaction :

The following medications have been administered concomitantly, with no increase in adverse reactions: ATG/ALG, Azathioprine, Corticosteroids, Cyclosporine, Mycophenolate Mofetil, And Muromonab-CD3.

03/14/2020 05:52:33 Basiliximab
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0